{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:20:45Z","timestamp":1783646445190,"version":"3.55.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/bf03344169","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T18:42:57Z","timestamp":1397155377000},"page":"665-674","source":"Crossref","is-referenced-by-count":19,"title":["Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol)"],"prefix":"10.1007","volume":"29","author":[{"given":"M.","family":"Maggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Crescioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Colli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Adorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,11]]},"reference":[{"key":"BF03344169_CR1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0015-0282(16)60147-4","volume":"50","author":"SJ Silber","year":"1988","unstructured":"Silber SJ, Balmaceda J, Borrero C, Ord T, Asch R. Pregnancy with sperm aspiration from the proximal head of the epididymis: a new treatment for congenital absence of the vas deferens. Fertil Steril 1988, 50: 525\u20138.","journal-title":"Fertil Steril"},{"key":"BF03344169_CR2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/01.ju.0000152318.79184.6f","volume":"173","author":"CS Saigal","year":"2005","unstructured":"Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005, 173: 1309\u201313.","journal-title":"J Urol"},{"key":"BF03344169_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1569-9056(02)00119-7","volume":"1","author":"RM Levin","year":"2004","unstructured":"Levin RM, Chichester P, Hass M, Gosling JA, Buttyan R. Obstructive bladder dysfunction: morphological, biochemical and molecular changes. Eur Urol 2004, 1(Suppl): 14\u201320.","journal-title":"Eur Urol"},{"key":"BF03344169_CR4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000020190","volume":"37","author":"J Morote","year":"2000","unstructured":"Morote J, Lopez M, Encabo G, de Torres IM. Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol 2000, 37: 537\u201340.","journal-title":"Eur Urol"},{"key":"BF03344169_CR5","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1097\/01.ju.0000127760.87421.e9","volume":"171","author":"R Taoka","year":"2004","unstructured":"Taoka R, Tsukuda F, Ishikawa M, Haba R, Kakehi Y. Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol 2004, 171: 2330\u20135.","journal-title":"J Urol"},{"key":"BF03344169_CR6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pros.20261","volume":"64","author":"G Untergasser","year":"2005","unstructured":"Untergasser G, Plas E, Pfister G, Heinrich E, Berger P. Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells. Prostate 2005, 64: 419\u201329.","journal-title":"Prostate"},{"key":"BF03344169_CR7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1097\/01.ju.0000133655.71782.14","volume":"172","author":"KL Lee","year":"2004","unstructured":"Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004, 172: 1784\u201391.","journal-title":"J Urol"},{"key":"BF03344169_CR8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1464-410X.2005.05341.x","volume":"95","author":"JC Nickel","year":"2005","unstructured":"Nickel JC, Elhilali M, Vallancien G; ALF-ONE Study Group. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int 2005, 95: 571\u20134.","journal-title":"BJU Int"},{"key":"BF03344169_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-642-55580-0_2","volume":"164","author":"C Carlberg","year":"2003","unstructured":"Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res 2003, 164: 29\u201342.","journal-title":"Recent Results Cancer Res"},{"key":"BF03344169_CR10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.semnephrol.2003.08.018","volume":"24","author":"AS Dusso","year":"2004","unstructured":"Dusso AS, Thadhani R, Slatopolsky E. Vitamin D receptor and analogs. Semin Nephrol 2004, 24: 10\u20136.","journal-title":"Semin Nephrol"},{"key":"BF03344169_CR11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/1568010043343930","volume":"3","author":"K Fogh","year":"2004","unstructured":"Fogh K, Kragballe K. New vitamin D analogs in psoriasis. Curr Drug Targets Inflamm Allergy 2004, 3: 199\u2013204.","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"BF03344169_CR12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1126\/science.6310748","volume":"221","author":"DM Provvedini","year":"1983","unstructured":"Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983, 221: 1181\u20133.","journal-title":"Science"},{"key":"BF03344169_CR13","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.4049\/jimmunol.133.4.1748","volume":"133","author":"AK Bhalla","year":"1984","unstructured":"Bhalla AK, Amento EP, Serog B, Glimcher LH. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 1984, 133: 1748\u201354.","journal-title":"J Immunol"},{"key":"BF03344169_CR14","doi-asserted-by":"crossref","first-page":"1704S","DOI":"10.1093\/jn\/125.suppl_6.1704S","volume":"125","author":"JM Lemire","year":"1995","unstructured":"Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995, 125: 1704S\u20138S.","journal-title":"J Nutr"},{"key":"BF03344169_CR15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/1521-4141(200002)30:2<498::AID-IMMU498>3.0.CO;2-Q","volume":"30","author":"F Mattner","year":"2000","unstructured":"Mattner F, Smiroldo S, Galbiati F, et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D3. Eur J Immunol 2000, 30: 498\u2013508.","journal-title":"Eur J Immunol"},{"key":"BF03344169_CR16","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1128\/MCB.15.10.5789","volume":"15","author":"I Alroy","year":"1995","unstructured":"Alroy I, Towers T, Freedman L. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition NFATp\/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995, 15: 5789\u201399.","journal-title":"Mol Cell Biol"},{"key":"BF03344169_CR17","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1002\/(SICI)1521-4141(199810)28:10<3017::AID-IMMU3017>3.0.CO;2-6","volume":"28","author":"M Cippitelli","year":"1998","unstructured":"Cippitelli M, Santoni A. Vitamin D3: a transcriptional modulator of the IFN-g gene. Eur J Immunol 1998, 28: 3017\u201330.","journal-title":"Eur J Immunol"},{"key":"BF03344169_CR18","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.4049\/jimmunol.167.9.4974","volume":"167","author":"A Boonstra","year":"2001","unstructured":"Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O\u2019Garra A. 1alpha,25-dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells. J Immunol 2001, 167: 4974\u201380.","journal-title":"J Immunol"},{"key":"BF03344169_CR19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.smim.2003.12.008","volume":"16","author":"L Adorini","year":"2004","unstructured":"Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004, 16: 127\u201334.","journal-title":"Semin Immunol"},{"key":"BF03344169_CR20","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.4049\/jimmunol.164.5.2405","volume":"164","author":"G Penna","year":"2000","unstructured":"Penna G, Adorini L. 1,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000, 164: 2405\u201311.","journal-title":"J Immunol"},{"key":"BF03344169_CR21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1006\/bbrc.2000.2490","volume":"270","author":"MD Griffin","year":"2000","unstructured":"Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000, 270: 701\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF03344169_CR22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jcb.10340","volume":"88","author":"L Adorini","year":"2003","unstructured":"Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 2003, 88: 227\u201333.","journal-title":"J Cell Biochem"},{"key":"BF03344169_CR23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev.nutr.23.011702.073114","volume":"23","author":"MD Griffin","year":"2003","unstructured":"Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 2003, 23: 117\u201345.","journal-title":"Annu Rev Nutr"},{"key":"BF03344169_CR24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nri910","volume":"2","author":"Q Li","year":"2002","unstructured":"Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002, 2: 725\u201334.","journal-title":"Nat Rev Immunol"},{"key":"BF03344169_CR25","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.4049\/jimmunol.173.4.2280","volume":"173","author":"N Giarratana","year":"2004","unstructured":"Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 2004, 173: 2280\u20137.","journal-title":"J Immunol"},{"key":"BF03344169_CR26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S1567-5769(02)00049-8","volume":"2","author":"L Adorini","year":"2002","unstructured":"Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol 2002, 2: 1017\u201328.","journal-title":"Int Immunopharmacol"},{"key":"BF03344169_CR27","first-page":"1458","volume":"3","author":"L Adorini","year":"2002","unstructured":"Adorini L. 1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr Opin Investig Drugs 2002, 3: 1458\u201363.","journal-title":"Curr Opin Investig Drugs"},{"key":"BF03344169_CR28","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/00007890-200210270-00030","volume":"74","author":"BN Becker","year":"2002","unstructured":"Becker BN, Hullett DA, O\u2019Herrin JK, Malin G, Sollinger HW, DeLuca H. Vitamin Das immunomodulatory therapy for kidney transplantation. Transplantation 2002, 74: 1204\u20136.","journal-title":"Transplantation"},{"key":"BF03344169_CR29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/ajcn\/79.3.362","volume":"79","author":"MF Holick","year":"2004","unstructured":"Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004, 79: 362\u201371.","journal-title":"Am J Clin Nutr"},{"key":"BF03344169_CR30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1210\/er.2004-0002","volume":"26","author":"S Nagpal","year":"2005","unstructured":"Nagpal S, Na S, Rathnachalam R. Non-calcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26: 662\u201387.","journal-title":"Endocr Rev"},{"key":"BF03344169_CR31","first-page":"2576","volume":"85","author":"C Crescioli","year":"2000","unstructured":"Crescioli C, Maggi M, Vannelli GB, et al. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab 2000, 85: 2576\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03344169_CR32","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1210\/jc.2004-1496","volume":"90","author":"C Crescioli","year":"2005","unstructured":"Crescioli C, Morelli A, Adorini L, et al. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005, 90: 962\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03344169_CR33","first-page":"805","volume":"54","author":"DM Peehl","year":"1994","unstructured":"Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994, 54: 805\u201310.","journal-title":"Cancer Res"},{"key":"BF03344169_CR34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/pros.20001","volume":"59","author":"MB Cheteri","year":"2004","unstructured":"Cheteri MB, Stanford JL, Friedrichsen DM, et al. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004, 59: 409\u201318.","journal-title":"Prostate"},{"key":"BF03344169_CR35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1677\/erc.0.0100131","volume":"10","author":"DM Peehl","year":"2003","unstructured":"Peehl DM, Feldman D. International Congress on Hormonal Steroids and Hormones and Cancer: The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 2003, 10: 131\u201340.","journal-title":"Endocr Relat Cancer"},{"key":"BF03344169_CR36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/jcb.10334","volume":"88","author":"AV Krishnan","year":"2003","unstructured":"Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 2003, 88: 363\u201371.","journal-title":"J Cell Biochem"},{"key":"BF03344169_CR37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00005392-200101000-00074","volume":"165","author":"BR Konety","year":"2001","unstructured":"Konety BR, Lavelle JP, Pirtskalaishvili G, et al. Effects of vitamin D (1,25-dihydroxyvitamin D3) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001, 165: 253\u20138.","journal-title":"J Urol"},{"key":"BF03344169_CR38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jcb.10342","volume":"88","author":"TC Chen","year":"2003","unstructured":"Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 2003, 88: 315\u201322.","journal-title":"J Cell Biochem"},{"key":"BF03344169_CR39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0960-0760(98)00054-5","volume":"66","author":"M Kivineva","year":"1998","unstructured":"Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P. Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 1998, 66: 121\u20137.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BF03344169_CR40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0039-128X(00)00226-9","volume":"66","author":"MR Uskokovic","year":"2001","unstructured":"Uskokovic MR, Norman AW, Manchand PS, et al. Highly active analogs of 1alpha, 25-dihydroxyvitamin D(3) that resist metabolism through C-24 oxidation and C-3 epimerization pathways. Steroids 2001, 66: 463\u201371.","journal-title":"Steroids"},{"key":"BF03344169_CR41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jcb.10344","volume":"88","author":"S Peleg","year":"2003","unstructured":"Peleg S, Ismail A, Uskokovic MR, Avnur Z. Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem 2003, 88: 267\u201373.","journal-title":"J Cell Biochem"},{"key":"BF03344169_CR42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1523-1755.2002.00450.x","volume":"62","author":"HH Malluche","year":"2002","unstructured":"Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Intern 2002, 62: 367\u201374.","journal-title":"Kidney Intern"},{"key":"BF03344169_CR43","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM198709033171004","volume":"317","author":"CA Peters","year":"1987","unstructured":"Peters CA and Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987, 317: 599\u2013604.","journal-title":"N Engl J Med"},{"key":"BF03344169_CR44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2265.1994.tb02521.x","volume":"41","author":"FH Schroder","year":"1994","unstructured":"Schroder FH. 5 alpha-reductase inhibitors and prostatic disease. Clin Endocrinol (Oxf) 1994, 41: 139\u201347.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03344169_CR45","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM197212212872508","volume":"287","author":"JD Wilson","year":"1972","unstructured":"Wilson JD. Recent studies on the mechanism of action of testosterone. N Engl J Med 1972, 287: 1284\u201391.","journal-title":"N Engl J Med"},{"key":"BF03344169_CR46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.ijir.3901017","volume":"15","author":"DJ Carbone Jr","year":"2003","unstructured":"Carbone DJ Jr, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 2003, 15: 299\u2013306.","journal-title":"Int J Impot Res"},{"key":"BF03344169_CR47","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(03)13073-5","volume":"361","author":"A Thorpe","year":"2003","unstructured":"Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003, 361: 1359\u201367.","journal-title":"Lancet"},{"key":"BF03344169_CR48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1095\/biolreprod22.1.19","volume":"22","author":"GR Cunha","year":"1980","unstructured":"Cunha GR, Chung LW, Shannon JM, Reese BA. Stromal-epithelial interactions in sex differentiation. Biol Reprod 1980, 22: 19\u201342.","journal-title":"Biol Reprod"},{"key":"BF03344169_CR49","first-page":"251","volume":"239","author":"GR Cunha","year":"1987","unstructured":"Cunha GR, Donjacour A. Stromal-epithelial interactions in normal and abnormal prostatic development. Prog Clin Biol Res 1987, 239: 251\u201372.","journal-title":"Prog Clin Biol Res"},{"key":"BF03344169_CR50","first-page":"3463","volume":"84","author":"M Marcelli","year":"1999","unstructured":"Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 1999, 84: 3463\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03344169_CR51","first-page":"423","volume":"1","author":"Y Sugimura","year":"1993","unstructured":"Sugimura Y, Cunha GR, Hayward N, et al. Keratinocyte growth factor (KGF) is a mediator of testosterone-induced prostatic development. Mol Cell Differ 1993, 1: 423\u20136.","journal-title":"Mol Cell Differ"},{"key":"BF03344169_CR52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00005392-199707000-00074","volume":"158","author":"S Claus","year":"1997","unstructured":"Claus S, Berges R, Senge T, Schulze H. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia. J Urol 1997, 158: 217\u201321.","journal-title":"J Urol"},{"key":"BF03344169_CR53","doi-asserted-by":"crossref","unstructured":"Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 147: 1293\u20137.","DOI":"10.1016\/S0022-5347(17)37546-8"},{"key":"BF03344169_CR54","first-page":"2186","volume":"83","author":"A Bellis De","year":"1998","unstructured":"De Bellis A, Crescioli C, Grappon C, et al. Expression and cellular localization of keratinocyte growth factor and its receptor in human hyperplastic prostate tissue. J Clin Endocrinol Metab 1998, 83: 2186\u201391.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03344169_CR55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1097-0045(19991201)41:4<233::AID-PROS3>3.0.CO;2-L","volume":"41","author":"B Planz","year":"1999","unstructured":"Planz B, Aretz HT, Wang Q, et al. Immunolocalization of the keratinocyte growth factor in benign and neoplastic human prostate and its relation to androgen receptor. Prostate 1999, 41: 233\u201342.","journal-title":"Prostate"},{"key":"BF03344169_CR56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1530\/eje.0.1500591","volume":"150","author":"C Crescioli","year":"2004","unstructured":"Crescioli C, Ferruzzi P, Caporali A, et al. Inhibition of prostate cell growth by BXL-628, a 1,25-dihydroxyvitamin D3 analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 2004, 150: 591.","journal-title":"Eur J Endocrinol"},{"key":"BF03344169_CR57","first-page":"778","volume":"78","author":"T Barni","year":"1994","unstructured":"Barni T, Vannelli BG, Sadri R, et al. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: gene expression and its cellular localization. J Clin Endocrinol Metab 1994, 78: 778\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03344169_CR58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/pros.10096","volume":"52","author":"AP Chokkalingam","year":"2002","unstructured":"Chokkalingam AP, Gao YT, Deng J, et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002, 52: 98\u2013105.","journal-title":"Prostate"},{"key":"BF03344169_CR59","first-page":"1700","volume":"86","author":"S Monti","year":"2001","unstructured":"Monti S, Di Silverio F, Iraci R, et al. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. J Clin Endocrinol Metab 2001, 86: 1700\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03344169_CR60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1677\/joe.0.1770389","volume":"177","author":"N Konno-Takahashi","year":"2003","unstructured":"Konno-Takahashi N, Takeuchi T, Shimizu T, et al. Engineered IGF-I expression induces glandular enlargement in the murine prostate. J Endocrinol 2003, 177: 389\u201398.","journal-title":"J Endocrinol"},{"key":"BF03344169_CR61","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/01.ju.0000137819.92305.46","volume":"172","author":"G Fromont","year":"2004","unstructured":"Fromont G, Chene L, Latil A, et al. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach. J Urol 2004, 172: 1382\u20135.","journal-title":"J Urol"},{"key":"BF03344169_CR62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9440(10)64535-X","volume":"157","author":"D Giri","year":"2000","unstructured":"Giri D, Ittmann M. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2000, 157: 249\u201355.","journal-title":"Am J Pathol"},{"key":"BF03344169_CR63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0002-9440(10)61681-1","volume":"159","author":"D Giri","year":"2001","unstructured":"Giri D, Ittmann M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001, 159: 139\u201347.","journal-title":"Am J Pathol"},{"key":"BF03344169_CR64","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1073\/pnas.112191399","volume":"99","author":"K Prakash","year":"2002","unstructured":"Prakash K, Pirozzi G, Elashoff M, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci USA. 2002, 99: 7598\u2013603.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF03344169_CR65","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1097\/01.ju.0000127760.87421.e9","volume":"171","author":"R Taoka","year":"2004","unstructured":"Taoka R, Tsukuda F, Ishikawa M, Haba R, Kakehi Y. Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol 2004, 171: 2330\u20135.","journal-title":"J Urol"},{"key":"BF03344169_CR66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0303-7207(02)00370-2","volume":"198","author":"C Crescioli","year":"2002","unstructured":"Crescioli C, Villari D, Forti G, et al. M Des (1\u20133) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D(3) analogue. Mol Cell Endocrinol 2002, 198: 69.","journal-title":"Mol Cell Endocrinol"},{"key":"BF03344169_CR67","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1210\/en.2002-0210","volume":"144","author":"C Crescioli","year":"2003","unstructured":"Crescioli C, Ferruzzi P, Caporali A, et al. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic 1,25-dihydroxyvitamin D3 analog. Endocrinology 2003, 144: 3046.","journal-title":"Endocrinology"},{"key":"BF03344169_CR68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/pros.10028","volume":"50","author":"C Crescioli","year":"2002","unstructured":"Crescioli C, Maggi M, Luconi M, et al. Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate 2002, 50: 15\u201326.","journal-title":"Prostate"},{"key":"BF03344169_CR69","doi-asserted-by":"crossref","unstructured":"Maggi M, Crescioli C, Adorini L. Inhibition of benign prostatic hyperplasia by vitamin D receptor ligands vitamin D. 2nd ed. Feldman, Pike and Glorieux eds. 2005, 104: 1833\u201343.","DOI":"10.1016\/B978-012252687-9\/50108-X"},{"key":"BF03344169_CR70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2005.08.014","volume":"49","author":"E Colli","year":"2006","unstructured":"Colli E, Rigatti P, Montorsi F, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomised clinical trial. Eur Urol 2006, 49: 5\u20137.","journal-title":"Eur Urol"},{"key":"BF03344169_CR71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1207\/s15327914nc5101_5","volume":"51","author":"TC Woo","year":"2005","unstructured":"Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 2005, 51: 32\u20136.","journal-title":"Nutr Cancer"},{"key":"BF03344169_CR72","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","volume":"60","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60: 434\u201341.","journal-title":"Urology"},{"key":"BF03344169_CR73","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0022-5347(17)37547-X","volume":"147","author":"E Stoner","year":"1992","unstructured":"Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992, 147: 1298\u2013302.","journal-title":"J Urol"},{"key":"BF03344169_CR74","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349: 2387\u201398.","journal-title":"N Engl J Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03344169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03344169\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03344169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T10:07:36Z","timestamp":1746180456000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03344169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["BF03344169"],"URL":"https:\/\/doi.org\/10.1007\/bf03344169","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}